Penserra Capital Management LLC acquired a new position in Allergan PLC. (NYSE:AGN) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 676 shares of the company’s stock, valued at approximately $164,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Honeywell International Inc. increased its stake in shares of Allergan PLC. by 13.6% in the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after purchasing an additional 20,100 shares in the last quarter. Israel Discount Bank of New York purchased a new stake in shares of Allergan PLC. in the first quarter worth $988,000. Palladium Partners LLC increased its stake in shares of Allergan PLC. by 1.7% in the second quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after purchasing an additional 523 shares in the last quarter. Trust Co. of Vermont increased its stake in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Capital Planning Advisors LLC increased its stake in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock worth $878,000 after purchasing an additional 1,625 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

AGN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research note on Tuesday, July 11th. BidaskClub raised shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a research note on Monday, June 12th. Mizuho reduced their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Finally, Cowen and Company set a $400.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a research note on Thursday, June 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $274.69.

Allergan PLC. (NYSE:AGN) opened at 220.29 on Friday. The firm has a 50 day moving average of $231.75 and a 200-day moving average of $236.59. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The stock has a market capitalization of $73.64 billion, a PE ratio of 6.71 and a beta of 1.18.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the firm earned $3.35 earnings per share. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, equities analysts predict that Allergan PLC. will post $16.25 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date was Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

TRADEMARK VIOLATION NOTICE: “Penserra Capital Management LLC Acquires New Position in Allergan PLC. (AGN)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/16/penserra-capital-management-llc-acquires-new-position-in-allergan-plc-agn.html.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.